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Abstract
Purpose Post-surgical adhesions remain a significant
concern following abdominopelvic surgery. This study was
to assess safety, manageability and explore preliminary
efficacy of applying a degradable hydrogel adhesion barrier
to areas of surgical trauma following gynecologic laparo-
scopic abdominopelvic surgery.
Methods This first-in-human, prospective, randomized,
multicenter, subject- and reviewer-blinded clinical study
was conducted in 78 premenopausal women (18–46 years)
wishing to maintain fertility and undergoing gynecologic
laparoscopic abdominopelvic surgery with planned clini-
cally indicated second-look laparoscopy (SLL) at
4–12 weeks. The first two patients of each surgeon
received hydrogel, up to 30 mL sprayed over all sites of
surgical trauma, and were assessed for safety and appli-
cation only (n = 12). Subsequent subjects (n = 66) were
randomized 1:1 to receive either hydrogel (Treatment,
n = 35) or not (Control, n = 31); 63 completed the SLL.
Results No adverse event was assessed as serious, or
possibly device related. None was severe or fatal. Adverse
events were reported for 17 treated subjects (17/47, 36.2%)
and 13 Controls (13/31, 41.9%). For 95.7% of treated
subjects, surgeons found the device ‘‘easy’’ or ‘‘very easy’’
to use; in 54.5%, some residual material was evident at
SLL. For 63 randomized subjects who completed the SLL,
adjusted between-group difference in the change from
baseline adhesion score demonstrated a 41.4% reduction
for Treatment compared with Controls (p = 0.017), with a
49.5% reduction (p = 0.008) among myomectomy sub-
jects (n = 34).
Conclusion Spray application of a degradable hydrogel
adhesion barrier during gynecologic laparoscopic abdomi-
nopelvic surgery was performed easily and safely, without
evidence of clinically significant adverse outcomes. Data
suggest the hydrogel was effective in reducing postopera-
tive adhesion development, particularly following
myomectomy.
Keywords Post-surgical adhesions  Hydrogel adhesion
barrier  Gynecological laparoscopic surgery  Second-look
laparoscopy  Adhesion barrier study
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Introduction
Postoperative adhesions represent a major health care
burden. They are the most frequent complication of
abdominopelvic surgery, and the cause of significant
patient morbidity including small bowel obstruction,
infertility, chronic abdominal pain, and prolonged and
complicated subsequent surgeries [1–4]. Gynecological
abdominopelvic surgeries, including uterine myomectomy,
ovarian cystectomy, lysis of adhesions and treatment of
endometriosis, are particularly adhesiogenic [3, 5, 6].
While there have been considerable advances in surgical
techniques including minimally invasive surgery, the risk
of adhesions and related complications remains high, and
for most therapeutic gynecological laparoscopic proce-
dures, the comparative risk is similar to gynecological
laparotomy [5] with approximately 20–40% of all infer-
tility resulting from adhesions that involve the Fallopian
tubes and ovaries [7–10].
In women wanting to preserve fertility, invasive proce-
dures of this nature may not only severely impact fecun-
dity, but they also put the patient at risk of other adhesion-
related complications, including complications during any
future abdominopelvic surgery [11–14]. Patients undergo-
ing removal of a posterior fibroid are at great risk of
adhesion formation, with high rates of adhesion formation
to the posterior uterus, rectosigmoid and adnexa [15–20].
Because of the high risk of adhesions and the negative
impact they have on clinical outcomes, many gynecologi-
cal surgeons will recommend a second-look laparoscopy
(SLL) a short time following the initial surgery, particu-
larly in patients undergoing fertility-related surgery. This
intervention provides the patient the opportunity to have a
surgeon assess and potentially treat de novo and reformed
adhesions or indeed other pathology resulting from the
prior surgical procedure. It also allows the surgeon to
assess the possibility of the patient conceiving without
assistance and carrying an infant to full term [6, 21, 22].
Lysis of adhesions at an early stage in their formation is
easier as they are more likely to be filmy and avascular, and
it appears more successful than if undertaken later [23–25].
This may improve clinical outcomes, improve fertility
[21, 26–28] and reduce other adhesion-related complica-
tions including the long-term risk of SBO and future re-
operative complications. In women with endometriosis
treated during surgery, a second-look procedure allows
evaluation and treatment of any early recurrence as part of
a protocol maximizing both cure rate and pregnancy out-
comes [29]. A second-look laparoscopy following a
myomectomy also allows the surgeon to examine the
integrity of the uterine scar, in order to counsel the patient
regarding attempting pregnancy [22, 30–32]. In subjects
with extensive adhesion development, the subject may be
advised to go directly to in vitro fertilization, adoption or
surrogacy.
The risk versus benefit of a second-look laparoscopy is
known. Adhesiolysis surgery in young, healthy women
wishing to retain their fertility is beneficial, but economi-
cally many health and or insurers systems do not reimburse
early second-look laparoscopy [28]. Undertaking a second-
look laparoscopy within the study protocol in subjects
where it is considered of clinical benefit, not only enables
close evaluation of the abdominopelvic cavity, but also
provides the opportunity for assessment of the potential
therapeutic value of the study investigational device.
The development of post-surgical adhesions is multi-
factorial. History of previous surgeries, length of surgery,
blood loss, suturing, surgical technique, length and location
of uterine incision, and the size, number and location of
myomas have all been shown to contribute to adhesion
development following myomectomy [16, 17, 19, 30, 33].
Over the past 10 years, gynecological experts have col-
laborated to produce proposals for national and interna-
tional guidance on adhesions and to assess the risk of
adhesions [1, 2, 20, 33–39]. As part of a comprehensive
adhesion reduction strategy using the basic tenets of
microsurgery, all recommend consideration of anti-adhe-
sion agents/barriers particularly in surgical procedures at
high risk for adhesion development.
ActamaxTM Adhesion Barrier (Actamax Surgical
Materials LLC, Wilmington, DE) is a new investigational
adhesion barrier device that is formed by mixing two
aqueous solutions, dextran aldehyde and polyethylene
glycol amine polymers, one of which contains a blue col-
orant. When sprayed together, the components form a thin,
formed-in-place, tissue-adherent degradable hydrogel that
directly overlies surgically traumatized tissue. This tem-
porary hydrogel barrier allows damaged and apposing tis-
sue surfaces the opportunity to heal without becoming
abnormally attached during the immediate postoperative
peritoneal healing period (3–5 days) [2, 40] when adhe-
sions are most likely to form.
This first-in-human feasibility study was conducted
primarily to assess the safety and manageability of the
hydrogel adhesion barrier (‘‘hydrogel’’) and its application
in a clinical setting. It was conducted in women wishing to
retain their fertility, who were undergoing gynecologic
laparoscopic surgery—including treatment of uterine
fibroids, ovarian cysts, endometriosis and adhesions—fol-
lowed by a clinically indicated SLL. Undertaking an SLL
enables close evaluation of safety within the abdomino-
pelvic cavity and provides the opportunity for assessment
of the potential therapeutic value of the investigational
device to be used in planning future studies [33]. From the
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patient’s perspective, the SLL serves as a valuable tool for
their surgeon to formulate a likely prognosis on natural
conception or need for assisted reproduction, as well as to
lyse adhesions and treat recurring pathology at an early
stage following the initial surgery [21, 22, 26, 28, 29].
Materials and methods
Trial design
This was a first-in-human, prospective, randomized (1:1),
multicenter, controlled (surgery only), subject- and
reviewer-blinded study. It was conducted between
November 2013 and June 2014.
Participants
Premenopausal women, aged 18–46 years, who wished to
maintain their fertility and were undergoing gynecologic
laparoscopic abdominopelvic surgery, with a planned
clinically indicated SLL at 4–12 weeks (16-week upper
limit), were eligible to be enrolled. Subjects who met all
selection criteria were assigned intraoperatively to 1 of 2
substudies (myomectomy or other gynecologic pathology),
and 1 of 2 arms of the myomectomy substudy (pure or
hybrid), based on the major component of their surgery. All
subjects provided written informed consent prior to
undergoing any protocol-related procedures.
Setting and ethical conduct
This study was conducted at centers in Germany (3) and
Greece (1); all were tertiary referral centers for complex
gynecologic laparoscopy. A total of 6 operating surgeons
participated. The study, which was approved by the Inde-
pendent Ethics Committees and relevant national regula-
tory authorities of each investigational site, was registered
with ClinicalTrials.gov (NCT02260115).
Procedures
The first two ‘‘initial usage’’ patients of each operating
surgeon were assigned to receive hydrogel following their
surgery and were assessed for its application and safety
only. Subsequent patients underwent randomization once
their primary surgery was complete and eligibility con-
firmed, including that an SLL was clinically indicated,
before removal of the laparoscope. Subjects within each
substudy and arm were randomized 1:1 to receive either
hydrogel, up to 30 mL sprayed over all sites of surgical
trauma (Treatment) or surgery only (Control). Follow-up
assessments were conducted at hospital discharge, at
12–16 days, and at the SLL (or at 30–60 days if no SLL
was undertaken). In cases where no SLL was performed,
subjects were assessed for safety only. Both the primary
surgery and SLL were video-recorded to allow for evalu-
ation of hydrogel application and a separate blinded
reviewer evaluation of adhesions and other pathologies
throughout the abdominopelvic cavity.
Interventions
For initial usage subjects and those randomized to Treat-
ment, up to 30 mL of hydrogel (Actamax Surgical Mate-
rials LLC, Wilmington, DE) was applied laparoscopically
to areas of the pelvis undergoing direct surgical trauma.
For those in the myomectomy substudy, hydrogel was to be
sprayed over the entire surface of the uterus and other areas
of surgical trauma. All sites of surgical trauma were to be
completely covered, allowing a margin of at least 3 cm
around the traumatized site. The hydrogel was applied
using a dual cannula CO2 gas-assisted endoscopic 5-mm
applicator which mixed the two prefilled 5-mL syringes:
one filled with an aqueous polymer solution of dextran
aldehyde and FD&C Blue #1 (blue in color); the other
filled with an aqueous polymer solution of two poly-
ethylene glycol amines (clear in color). The syringe set,
which was attached to a laparoscopic spray applicator and
pressure regulator, was designed for use with the operating
room carbon dioxide source. Subjects randomized to the
Control underwent the primary gynecologic laparoscopic
surgery without any further protocol-specified intervention.
Outcomes
The primary study outcomes were safety related. These
included the incidence of adverse events, and any abnormal
vital signs or laboratory measures considered clinically
significant by the operating surgeon. Secondary safety
outcomes included surgeon experience with hydrogel
application, presence of any residual material at SLL,
postoperative pain, duration of hospital stay, and port site
healing. Hydrogel application was assessed using a 5-point
scale ranging from 1 = ‘‘very difficult’’ to 5 = ‘‘very easy’’.
Operating surgeons rated their overall satisfaction, viewing
and handling of the device as well as various aspects of
functionality. Based on these ratings, a mean ease of use
score was also calculated. In the case of residual material,
the operating surgeon recorded the qualitative amount and
location of any material evident at the SLL. The blinded
reviewer noted whether the considered material was pre-
sent in the SLL videos and the study sponsor undertook an
unblinded review of these same videos to estimate the
volume of material based on comparisons with the known
dimensions of the laparoscopic instruments present in the
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video. Efficacy outcomes were considered secondary.
These included the formation of adhesions evident at the
SLL, at each of 16 pre-specified anatomical sites and 5
regions (Supplemental Online Table 1). Adhesions were
summarized by incidence, severity, extent and adhesion
score. Adhesion efficacy outcomes were based on the
change from baseline at SLL in the adhesion score, cal-
culated as the combined score of the severity and extent of
adhesions at that site or region.
Sample size
It was prospectively estimated that 75 enrolled subjects
were needed so that at least 60 subjects, randomized into
equal numbers to receive surgery with or without hydrogel,
underwent the SLL. Of the 75, it was expected that less
than 5% (approximately 3 subjects) would not complete the
study and that, with 6 operating surgeons, 12 subjects
would serve as initial usage subjects. For an adverse out-
come that occurs in 5% of treated subjects, this sample
ensured that there was[90% power to observe an event in
at least one of the 42 treated subjects (12 initial usage plus
30 randomized).
Randomization
Randomization was stratified by surgeon and by surgical
subgroup. Randomization was conducted in permuted
blocks of size two within each stratum, to ensure approx-
imate treatment balance within each surgeon/subgroup at
the end of the study. That is, for each surgeon, every two
consecutive randomized subjects within each subgroup
were allocated 1:1 between Treatment and Control. The
block size was intentionally small to accommodate the
small number of subjects recruited by each surgeon for this
first-in-human study. Allocations were obtained by tele-
phone to an interactive voice response system or via the
electronic case report form managed by the Robertson
Centre for Biostatistics, University of Glasgow, so that
allocations were concealed from study sites until the time
of randomization; clinical sites were not informed of the
permuted block size.
Blinding
Study subjects remained blinded to their treatment alloca-
tion beyond study completion. Of necessity, the operating
surgeon was not blinded. For all subjects who received
hydrogel, the application video segment from the primary
surgery was removed and sent to an evaluator assigned to
assess the quality of hydrogel application. Following the
SLL, copies of paired videos for the primary surgery (with
application section removed) and SLL were provided to the
blinded evaluator assigned to assess adhesions.
Statistical methods
Data were summarized for baseline characteristics, the
primary surgery including hydrogel application, and safety
and efficacy outcomes. Adverse event data were tabulated.
Categorical data were compared between randomized
groups using Fisher’s exact test; continuous data were
compared between randomized groups using the Wil-
coxon–Mann–Whitney test. For efficacy analyses, changes
in adhesion scores were compared between randomized
groups using linear regression models, adjusted for sub-
study and baseline adhesions scores, and reported as the
estimated treatment effect difference with a 95% confi-
dence interval and p value. Analyses were carried out using
R for Windows v3.0.0 and SAS for Windows v9.2.
Results
Participants
The flow of study subjects from initial screening to study
completion is illustrated in Fig. 1. A total of 80 patients
were screened for enrollment; two were screen failures.
The remaining 78 subjects formed the Safety Population.
Approximately half (41, 52.6%) were allocated to the
myomectomy substudy. The 63 randomized patients who
completed the SLL formed the Efficacy population (33
Treatment; 30 Control). In total, 74 subjects (74/78, 95%)
including 11 initial usage subjects, underwent the SLL and
completed the study; 4 enrolled subjects (5%) refused the
SLL and were included in the Safety Population.
Baseline characteristics
The 78 study subjects had a mean age of 33.6 years
(Supplemental Online Table 2); almost all (76/78, 97.4%)
were racially identified as ‘‘white.’’ Their mean weight
and BMI were 68.9 kg and 24.8 kg/m2, respectively.
Among randomized subjects, more Treatment subjects
were smokers (16/35, 45.7% vs. 5/31 Control, 16.1%);
fewer Treatment subjects had a history of treatment for
uterine fibroids (2/35, 5.7% vs. 7/31 Control, 22.6%).
Otherwise, differences between groups and substudies in
baseline characteristics were unremarkable. All baseline
vital signs were assessed as of no clinical concern, and no
baseline laboratory measure that was outside the normal
range was judged as clinically significant by the treating
surgeon.
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Primary gynecological laparoscopy record
The mean duration of the primary surgery was
90.8 ± 48.7 min (Table 1). Fifty-one subjects (51/78,
65.4%) underwent surgical removal of fibroids, with no
difference in the percentages of Treatment and Control
subjects undergoing this procedure (62.9% vs. 74.2%,
respectively, p = 0.429). For the 72 subjects (72/78,
92.3%) whose primary surgery videos underwent inde-
pendent review, 52 (52/72, 72.2%) had at least one
adhesion; the mean number of anatomical sites with
baseline adhesions was 3.1 ± 3.1. Despite randomization,
statistically significantly more subjects in the Treatment
group had baseline adhesions: 29/33, 87.9% vs. 18/30
Control, 60.0%, p = 0.019. Treatment subjects also had
more anatomical sites with baseline adhesions, and a
greater maximum severity, mean extent, and mean adhe-
sion score. Among substudies, differences between Treat-
ment and Controls were particularly marked in other
gynecologic pathology subjects.
Assessed for Eligibility
N=80
Analyzed for Safety
N=78
41 Myomectomy (15 Pure, 26 Hybrid)
37 Other Gynecologic Pathology
Initial Usage
N=12 
6 Myomectomy (1 Pure, 5 Hybrid)
6 Other Gynecologic Pathology
Randomized
N=66 
35 Myomectomy (14 Pure, 21 Hybrid)
31 Other Gynecologic Pathology
Allocated to Treatment
N=35
All received intervention as allocated 
19 Myomectomy (7 Pure, 12 Hybrid)
16 Other Gynecologic Pathology
Allocated to Control
N=31
All received intervention as allocated 
16 Myomectomy (7 Pure, 9 Hybrid)
15 Other Gynecologic Pathology
Completed SLL
N=33 
18 Myomectomy (6 Pure, 12 Hybrid)
15 Other Gynecologic Pathology
Completed SLL
N=11 
5 Myomectomy (1 Pure, 4 Hybrid)
6 Other Gynecologic Pathology
Completed SLL
N=30 
16 Myomectomy (7 Pure, 9 Hybrid)
14 Other Gynecologic Pathology
Subject refused the SLL
and was withdrawn
at their request 
N=2 
1 Myomectomy (1 Pure, 0 Hybrid)
1 Other Gynecologic Pathology
0 lost to follow-up
0 discontinued intervention
Subject refused the SLL
and was withdrawn
at their request 
N=1 
1 Myomectomy (0 Pure, 1 Hybrid)
0 Other Gynecologic Pathology
0 lost to follow-up
0 discontinued intervention
Subject withdrawn prior
to SLL due to
protocol violation 
N=1 
0 Myomectomy (0 Pure, 0 Hybrid)
1 Other Gynecologic Pathology
0 lost to follow-up
0 discontinued intervention
Analyzed for Efficacy
N=63 
34 Myomectomy (13 Pure, 21 Hybrid)
29 Other Gynecologic Pathology
A total of 15 subjects were excluded:
3 Randomized who did not complete
the SLL and the 12 Initial Usage
Excluded – i.e., screen failures
N=2
1 – surgical decision (bowel endometriosis)
1 – other (CRP outside the normal range)
Enrollment
Allocation
Follow-up
Efficacy Analysis
Fig. 1 CONSORT flow diagram
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Table 1 Primary surgery record—surgical procedures and summary of adhesions for the entire abdominal cavity
All (N = 78) Initial usage
(N = 12)
Randomized (N = 66)
Treatment
(N = 35)
Control
(N = 31)
p value
Surgical procedure/characteristic
Myomectomya, n (%) 51 (65.4%) 6 (50.0%) 22 (62.9%) 23 (74.2%) 0.429e
No. of fibroids removed, mean ± SD [min, max] 3.0 ± 2.1
[1, 10]
2.8 ± 1.9
[1, 6]
2.9 ± 2.0
[1, 8]
3.1 ± 2.3
[1, 10]
0.824f
Total wt. of fibroids (g), mean ± SD [min, max] 77.3 ± 69.2
[3, 300]
98.8 ± 103.0
[8, 300]
64.4 ± 56.8
[7, 226]
83.9 ± 71.0
[3, 232]
0.625f
Surgery for ovarian cysts, n (%) 14 (17.9%) 4 (33.3%) 7 (20.0%) 3 (9.7%) 0.314e
No. of cysts removed, mean ± SD [min, max] 1.3 ± 0.5
[1, 2]
1.5 ± 0.7
[1, 2]
1.4 ± 0.6
[1, 2]
1.0 ± 0.0
[1, 1]
0.324f
Adhesiolysis, n (%) 48 (61.5%) 4 (33.3%) 27 (77.1%) 17 (54.8%) 0.070e
Surgery for endometriosis, n (%) 40 (51.3%) 5 (41.7%) 17 (48.6%) 18 (58.1%) 0.469e
Diagnostic hysteroscopy, n (%) 45 (57.7%) 6 (50.0%) 21 (60.0%) 18 (58.1%) 1.000e
Other gynecologic procedure, n (%) 1 (1.3%) 1 (8.3%) 0 (0.0%) 0 (0.0%) 1.000e
Duration of surgery (min), mean ± SD [min, max] 90.8 ± 48.7
[16, 229]
91.1 ± 37.3
[35, 156]
91.7 ± 44.9
[43, 207]
89.8 ± 57.3
[16, 229]
0.537f
Adhesion parameter at initial surgery
Any adhesions present, n (% of those with C1 assessable site) 52/72 (72.2%) 5/9 (55.6%) 29/33 (87.9%) 18/30 (60.0%) 0.019e
No. of sites with adhesions, mean ± SD [min, max] 3.1 ± 3.1
[0, 11]
2.2 ± 2.7
[0, 7]
4.2 ± 3.4
[0, 11]
2.3 ± 2.6
[0, 10]
0.016f
Maximum severity scoreb, mean ± SD
All (N = 72)
Pure myomectomy (n = 14)
Hybrid myomectomy (n = 24)
Other gynecologic pathology (n = 34)
1.42 ± 1.06
0.36 ± 0.74
1.29 ± 0.91
1.94 ± 0.92
1.22 ± 1.20
–
0.67 ± 1.15
1.80 ± 1.10
1.82 ± 0.95
0.83 ± 0.98
1.58 ± 0.79
2.40 ± 0.63
1.03 ± 1.00
0.00 ± 0.00
1.11 ± 0.93
1.50 ± 0.94
0.003f
0.053f
0.284f
0.009f
Mean extent scorec, mean ± SD
All (N = 72)
Pure myomectomy (n = 14)
Hybrid myomectomy (n = 24)
Other gynecologic pathology (n = 34)
0.25 ± 0.32
0.03 ± 0.05
0.19 ± 0.26
0.38 ± 0.37
0.23 ± 0.34
–
0.04 ± 0.07
0.39 ± 0.39
0.32 ± 0.36
0.06 ± 0.07
0.19 ± 0.09
0.52 ± 0.44
0.18 ± 0.27
0.00 ± 0.00
0.25 ± 0.41
0.22 ± 0.20
0.020f
0.051f
0.446f
0.027f
Adhesion scored, mean ± SD
All (N = 72)
Pure myomectomy (n = 14)
Hybrid myomectomy (n = 24)
Other gynecologic pathology (n = 34)
1.67 ± 1.29
0.38 ± 0.80
1.48 ± 1.04
2.32 ± 1.19
1.45 ± 1.44
–
0.71 ± 1.23
2.19 ± 1.33
2.14 ± 1.19
0.90 ± 1.05
1.77 ± 0.82
2.92 ± 0.98
1.21 ± 1.19
0.00 ± 0.00
1.36 ± 1.19
1.72 ± 1.09
0.004f
0.053f
0.352f
0.006f
a Only 41 of the 51 subjects who underwent a myomectomy procedure during their primary surgery were assigned to the myomectomy substudy
based on myomectomy being the major component of that surgery
b Severity was assessed on 4-point scale: 0 = no adhesions; 1 = filmy/no vascularity; 2 = dense/vascular; 3 = cohesive (i.e., two surfaces
directly adhered with no clear bands)
c Extent was also assessed on a 4-point scale: 0 = none; 1 = B1/3 area of anatomical site; 2 = 1/3–2/3 area of anatomical site; 3 = C2/3 area
of anatomical site
d Adhesion score = maximum severity ? mean extent scores at all assessable sites
e Fisher’s exact test p values
f Wilcoxon–Mann–Whitney test p values
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Table 2 Adverse events
All (N = 78) Initial usage (N = 12) Randomized (N = 66)
Treatment (N = 35) Control (N = 31)
Number of patients who had an AE 30 (38.5%) 2 (16.7%) 15 (42.9%) 13 (41.9%)
Number of adverse events 43 2 24 17
Adverse device effect 0 0 0 0
Serious adverse event 0 0 0 0
Relationship with investigational device, n (%)a
Not related
Unlikely to be related
Possibly/probably related
37 (86.0%)
6 (14.0%)
0
2 (100%)
0
0
19 (79.2%)
5 (20.8%)
0
16 (94.1%)
1 (5.9%)
0
Relationship with study procedure, n (%)a
Not related
Unlikely to be related
Possibly/probably related
37 (86.0%)
6 (14.0%)
0
2 (100%)
0
0
19 (79.2%)
5 (20.8%)
0
16 (94.1%)
1 (5.9%)
0
Relationship with other device/agent used, n (%)a
Not related
Unlikely to be related
Possibly related
Probably/highly related
32 (74.4%)
6 (14.0%)
0
5 (11.6%)
2 (100%)
0
0
0
15 (62.5%)
5 (20.8%)
0
4 (16.7%)
15 (88.2%)
1 (5.9%)
0
1 (5.9%)
Severity, n (%)a
Mild
Moderate
Severe
28 (65.1%)
15 (34.9%)
0
1 (50%)
1 (50%)
0
15 (62.5%)
9 (37.5%)
0
12 (70.6%)
5 (29.4%)
0
Commonly occurring events (C5% of subjects) by system organ class and preferred termb
Infections and infestations
Influenza
Nasopharyngitis
Urinary tract infection
Viral infection
7 (9.0%)
2 (2.6%)
2 (2.6%)
2 (2.6%)
1 (1.3%)
0 4 (11.4%)
2
1
0
1
3 (9.7%)
0
1
2
0
Nervous system disorders
Dizziness
Headache
Paresthesia
6 (7.7%)
1 (1.3%)
4 (5.1%)
1 (1.3%)
0 3 (8.6%)
0
2
1
3 (9.7%)
1
2
0
Gastrointestinal disorders
Abdominal pain
Constipation
Vomiting
4 (5.1%)
2 (2.6%)
1 (1.3%)
1 (1.3%)
0 1 (2.9%)
1
0
0
3 (9.7%)
1
1
1
Immune system disorders
Drug hypersensitivity
Hypersensitivity
Seasonal allergy
4 (5.1%)
1 (1.3%)
2 (2.6%)
1 (1.3%)
0 2 (5.7%)
1
1
0
2 (6.5%)
0
1
1
Reproductive system and breast disorders
Dysmenorrhea ? metrorrhagia
Ovarian cyst
Uterine disorder
4 (5.1%)
1 (1.3%)
2 (2.6%)
1 (1.3%)
0 3 (8.6%)
1
1
1
1 (3.2%)
0
1
0
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Adverse events
Thirty subjects (30/78, 38.5%) experienced a total of 43
adverse events, including 2 events in 2 initial usage
subjects (2/12, 16.7%) (Table 2). The proportion of ran-
domized subjects who experienced at least one event was
no different between groups: 24 events were reported for
15 Treatment subjects (15/35, 42.9%); 17 events were
reported for 13 Controls (13/31, 41.9%). In total, 26
events were reported for 17 hydrogel-treated subjects (2/
12 initial usage ? 15/35 Treatment, 17/47, 36.2%). No
event was assessed as serious, or as possibly/probably
related to the investigational device or to any study pro-
cedures. None was fatal or assessed as severe. Five events
were deemed either highly probably or probably related to
another device or agent used: 1 case of metrorrhagia,
dysmenorrhea and abdominal pain, 1 of suture granuloma,
and 1 of phlebitis (all Treatment subjects); 2 cases of
hypersensitivity reaction to sutures (1 Treatment, 1 Con-
trol). The most common adverse events, occurring in 5%
or more of subjects (n = 4), were ‘‘infections and infes-
tations’’ reported for seven patients (Table 2). These
included influenza, nasopharyngitis, urinary tract infection
and viral infection. The second most common events were
‘‘nervous system disorders’’ reported for six patients,
which included headache, dizziness, and paresthesia.
There were no differences in the percentages of ran-
domized Treatment and Control subjects who experienced
events in either of these classes.
Vital signs and clinical laboratory measures
As at baseline, no vital sign measures at the SLL were
assessed as abnormal or of clinical concern. Most subjects
had at least one laboratory measurement outside the normal
range at either the discharge visit (75/78, 96.2%) or SLL
(66/78, 84.6%); no abnormal measure was judged by the
treating surgeon to be of clinical significance.
Hydrogel application
Hydrogel was applied in 47 subjects: 12 initial usage and
35 randomized to Treatment. A mean of 11.3 ± 4.3 mL
was applied (range of 4–20 mL); application was complete
in a mean of 6.2 ± 2.8 min (range of 1–15 min). A single
syringe set (10 mL of product) was used for 33 of the 47
subjects (70.2%); two syringe sets were used for the other
14 (29.8%). Operating surgeons were satisfied with
hydrogel manageability, assigning a rank of ‘‘easy’’ or
‘‘very easy’’ for each of overall satisfaction, viewing and
handling for 45 of the 47 subjects (95.7%) in whom it was
applied (Supplemental Fig. 1). Where 12 specific aspects
of functionality were assessed, the mean ease of use score
was 4.4 (1 = ‘‘very difficult’’, 5 = ‘‘very easy’’): 4.2 for
initial usage subjects and 4.5 for Treatment subjects
(Wilcoxon–Mann–Whitney test p = 0.039, data not
displayed).
Residual material at SLL
A total of 44 subjects (11 initial usage, 33 Treatment) who
received hydrogel following their primary surgery under-
went the SLL. For 20 subjects (20/44, 45.5%), the blinded
independent reviewer of the SLL videos found no evidence
of residual material at any anatomical site. For the other 24
(24/44, 54.5%), residual material was observed at a mean
of two sites (range of 0–12 sites). There was no evidence
that the presence of residual material was associated with
the substudy (p = 0.666), the volume of hydrogel applied
(\10, =10,[10 mL; p = 0.646) or with the duration
between the primary surgery and SLL (B8,[8
and B10,[10 weeks; p = 0.692). Residual material was
found more commonly at sites where hydrogel had been
applied during the primary surgery. Based on the unblinded
review of the SLL videos, the volume of residual material
was estimated to be a mean of 1.0 mL, representing 9.1%
of the mean volume applied during the primary surgery.
Table 2 continued
All (N = 78) Initial usage (N = 12) Randomized (N = 66)
Treatment (N = 35) Control (N = 31)
Skin and subcutaneous tissue disorders
Erythema ? pruritus
Rash
Rash pruritic
4 (5.1%)
1 (1.3%)
2 (2.6%)
1 (1.3%)
0 2 (5.7%)
0
2
0
2 (6.5%)
1
0
1
a As determined by operating surgeon, displayed as a percent of events
b As determined by operating surgeon, displayed as a percent of subjects
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There was no indication that any adverse outcomes were
associated with the presence of residual material; no intra-
abdominal or postoperative infections at the operative site
were observed in any subject.
Other safety outcomes
Pain was assessed as ‘‘greater than expected’’ for one
Control subject at hospital discharge, and for three subjects
(two Treatment, one Control) at SLL. No subject experi-
enced abdominal pain that was deemed to be ‘‘of clinical
concern’’. Hospital stay was assessed as ‘‘longer than
expected’’ in only two subjects (2.6%)—both Controls
(neither was considered a serious adverse event). The pri-
mary surgery had been conducted using three ports in 29
subjects (29/78, 37.2%), four ports in 46 subjects (46/78,
59.0%) and five ports in 3 (3/78, 3.8%). At hospital dis-
charge, port site healing was assessed as ‘‘uncomplicated’’
in 97.4% of subjects (35/35 Treatment, 100%; 28/30
Control, 93.3%) and as ‘‘complicated’’ for two Control
subjects; no subject experienced port site healing that was
assessed to be ‘‘of clinical concern’’ at either the time of
discharge or the SLL.
Efficacy
For the Efficacy Population (n = 63), from the initial
surgery to SLL, Treatment subjects showed a mean
reduction in adhesion score at sites of surgery throughout
the abdominal cavity of 0.51 ± 1.62 points; in marked
contrast, Control subjects showed an increase of
0.95 ± 1.89 points (Table 3). Based on linear regression
analysis, adjusting for substudy and baseline adhesion
score, the adhesion score in the Treatment group was
estimated to be 0.96 (95% CI 0.18, 1.74) points lower than
in the Control group (p = 0.017); this difference repre-
sented 41.4% of the mean adhesion score for Control
patients. For myomectomy substudy subjects (n = 34),
where the primary efficacy endpoint was limited to the
posterior uterus site, the adjusted difference between
groups represented a 38.2% reduction in adhesion score for
Treatment subjects compared with Controls (p = 0.086).
When the analysis for myomectomy substudy subjects was
expanded to include all sites of surgery throughout the
abdominal cavity, the adjusted difference between groups
represented a statistically significant 49.5% reduction in
adhesion score for Treatment subjects compared with
Controls (p = 0.008). No statistically significant differ-
ences were observed for either of the primary efficacy
outcomes assessed for Other Gynecological Pathology
substudy subjects. Regardless of whether or not treated
subjects had evidence of residual material present at SLL,
scoring of adhesions by the independent video reviewer did
not differ significantly for any of the efficacy outcomes
assessed (Supplemental Online Tables 3 and 4).
Discussion
Usage data collected for the 47 subjects in whom hydrogel
was administered, indicate that application during gyne-
cologic laparoscopic surgery was neither difficult nor time
consuming, and was performed safely without evidence of
any serious adverse events or clinically significant adverse
outcomes for any safety measure assessed.
As this was a first-in-human study, one key component
was the evaluation of the surgeons’ ability to handle the
device effectively. When ‘‘ease of use’’ assessments were
converted to numerical scores for the 12 specific aspects of
device functionality assessed, the mean score for initial
usage subjects was statistically significantly lower than that
of randomized Treatment subjects, suggesting that sur-
geons found the device easier to use with practice. Still, it
is clear from the data displayed in Supplemental Online
Fig. 1 that surgeons performed all aspects of application
with a high degree of ease for almost all subjects. For
example, in 89.4% of cases, surgeons reported that
manipulation of the sprayer tip was either ‘‘easy’’ or ‘‘very
easy’’, with the remaining cases assessed as ‘‘okay’’.
Our data suggest that in this first-in-human study,
hydrogel application was of particular benefit in
myomectomy patients. When evaluated for all subjects in
the Efficacy Population as well as for those in the
myomectomy substudy, statistically significant treatment-
related reductions in the change from baseline adhesion
scores of 41.4% and 49.5%, respectively, were observed in
these populations (p = 0.017 and p = 0.008, respectively).
These data indicate performance that is equal or better than
in other studies, reported between 2003 and 2008, in which
gel-based post-surgical adhesion barriers were applied
[17, 41–47].
Limitations to this study include that, although efficacy
analyses were adjusted for baseline mean adhesion scores,
we cannot exclude the possibility that differences between
groups in the number, severity and extent of adhesions at
baseline influenced our conclusions. In addition, this
78-patient first-in-human study was not powered on the
basis of detecting differences between randomized groups
for efficacy outcomes. It is also recognized that while this
study was designed with a[90% power to observe an
adverse event that occurs in 5% of treated subjects, the
power to detect the event in this small sample size has a
95% confidence interval of between 0 and 12%. It is our
contention that these data are sufficiently promising that a
larger clinical efficacy and safety study is warranted to
corroborate these findings.
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Another potential limitation of this study was that the
assessment of efficacy outcomes might have been influ-
enced by the presence of small amounts of residual mate-
rial at the SLL. The independent ‘‘blinded’’ reviewer
assessing postoperative adhesions on SLL videotape whilst
being blind to the randomization allocation of the patient
would believe, if they observed any residual material to be
present, that a subject had received hydrogel during their
primary surgery. To investigate the possibility of bias from
such knowledge, the primary efficacy analyses were
Table 3 Efficacy analyses—
adhesion scores at sites of
surgery
Adhesion scorea by study population Treatment Control p value
All efficacy subjects, n 33 30
Adhesion score, abdominal cavity, mean ± SD
Primary surgery 2.34 ± 1.45 1.36 ± 1.40 0.008b
SLL 1.83 ± 1.50 2.32 ± 1.48 0.228b
Change – 0.51 ± 1.62 0.95 ± 1.89 0.002b
Unadjusted between-group difference 1.46
Adjusted between-group difference (95% CI)c 0.96 (0.18, 1.74) 0.017
–as % of adhesion score for controls at SLL ; 41.4%
Myomectomy substudy subjects (pure ? hybrid), n 18 16
Adhesion score, posterior uterus, mean ± SD
Primary surgery 0.33 ± 0.77 0.19 ± 0.75 0.422b
SLL 1.61 ± 1.38 2.56 ± 1.71 0.058b
Change 1.28 ± 1.56 2.38 ± 1.82 0.068b
Unadjusted between-group difference 1.10
Adjusted between-group difference (95 % CI)c 0.98 (-0.15, 2.10) 0.086
–as % of adhesion score for controls at SLL ; 38.2%
Adhesion score, abdominal cavity, mean ± SD
Primary surgery 1.52 ± 1.22 0.90 ± 1.30 0.097b
SLL 1.54 ± 1.32 2.74 ± 1.36 0.010b
Change 0.02 ± 1.65 1.85 ± 1.62 0.003b
Unadjusted between-group difference 1.83
Adjusted between-group difference (95 % CI)c 1.36 (0.37, 2.34) 0.008
–as % of adhesion score for controls at SLL ; 49.5%
Other gynecologic pathology substudy subjects, n 15d 14d
Adhesion score, combined adnexa, mean ± SD
Primary surgery 2.97 ± 1.67 3.10 ± 1.14 1.000b
SLL 2.81 ± 1.79 1.80 ± 1.96 0.342b
Change -0.17 ± 2.21 -1.30 ± 1.72 0.401b
Unadjusted between-group difference -1.13
Adjusted between-group difference (95 % CI)c -1.04 (-3.10, 1.02) 0.298
–as % of adhesion score for controls at SLL : 57.9%
Adhesion score, abdominal cavity, mean ± SD
Primary surgery 3.32 ± 1.05 1.90 ± 1.35 0.009b
SLL 2.18 ± 1.67 1.83 ± 1.51 0.400b
Change -1.14 ± 1.38 -0.07 ± 1.67 0.149b
Unadjusted between-group difference 1.07
Adjusted between-group difference (95 % CI)c 0.46 (-0.86, 1.77) 0.482
–as % of adhesion score for controls at SLL ; 24.9%
a Maximum severity ? mean extent at sites of surgery with adhesions at the SLL for the specified region or
site
b Between group comparisons based on Wilcoxon–Mann–Whitney tests
c Estimate based on linear regression model adjusting for substudy and baseline score
d Not all subjects had adnexal adhesions (n = 13 Treatment, 5 Control at the combined adnexa)
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repeated, splitting the Treatment group into those where
residual material was or was not observed. No evidence
was found that observation of residual material affected the
efficacy of the ActamaxTM Adhesion Barrier as assessed by
the independent reviewer’s scoring of adhesions.
Our observations suggest that a thin flexible tissue-ad-
herent bioabsorbable hydrogel that can be laparoscopically
applied, such as the ActamaxTM Adhesion Barrier, will
prove to be an important anti-adhesion surgical adjuvant to
reduce postoperative adhesion development.
Conclusion
In summary, in this first-in-human clinical study, spray
application of a degradable polyethylene glycol-based
hydrogel adhesion barrier during laparoscopic gynecologic
surgery was performed easily, safely and without evidence
of any clinically significant adverse outcomes. Our data
also suggest that the hydrogel was effective in reducing
adhesions, particularly following myomectomy. Further
study is warranted to corroborate these promising initial
results.
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